Raloxifene

CAS : 84449-90-1

Ref. 3D-FR175031

Informations sur le produit

• Nom: Raloxifene
• Marque: Biosynth
• Description: Raloxifene is a non-steroidal drug that binds to estrogen receptors, which may be useful in the treatment of postmenopausal osteoporosis. Raloxifene has been shown to increase bone mineral density and reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. Raloxifene also has been found to decrease breast cancer risk by about 50% in postmenopausal women. The drug binds to estrogen receptors in breast tissue, preventing the stimulation of these cells by estrogen and decreasing their growth rate. Raloxifene also inhibits the production of lactogenic hormones such as prolactin and progesterone that are involved in breast cancer development. Raloxifene hydrochloride is used at doses between 60 mg and 120 mg per day for a duration of 5 years.Raloxifene hydrochloride is not active against estrogen receptor positive tumors and should not be used for treatment of breast cancer.

Propriétés chimiques

• Masse moléculaire: 473.58 g/mol
• Formule: C₂₈H₂₇NO₄S
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder
• InChI: InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
• Code InChI: InChIKey=GZUITABIAKMVPG-UHFFFAOYSA-N
• SMILES: O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12